<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909556</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01</org_study_id>
    <nct_id>NCT02909556</nct_id>
  </id_info>
  <brief_title>ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic Stenosis</brief_title>
  <official_title>ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cinical trial aimed at evaluating the safety and performance of the ACURATE neo™ AS Aortic
      Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System for CE mark approval
      purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single arm, prospecitve, multicenter, non-randomized and open trial. The purpose of this
      trial is to collect and safety and performance data concerning the ACURATE neo™ AS Aortic
      Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System

      The ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery
      SystemACURATE neo™ are intended for use in minimally invasive, transcatheter aortic valve
      replacement (TAVR) using transfemoral access in patients presenting with severe aortic valve
      stenosis.

      The primary objective is to evaluate the safety and performance of the study device in
      patients presenting with severe aortic stenosis (AS) considered to be high risk for surgery.

      The secondary objective is to evaluate adverse events and study device performance.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Actual">January 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of all-cause mortality at 30 days follow-up</measure>
    <time_frame>30 days post-implant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical events as defined per VARC guidelines</measure>
    <time_frame>7 days, 30 days, 12 months post-implant</time_frame>
    <description>Clinical events:
Mortality
Stroke
Myocardial infarction
Bleeding complication
Acute kidney injury
Vascular complication
Conduction disturbances and arrhythmia
Other TAVI-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>Day of implant</time_frame>
    <description>2. Procedural success defined as absence of complications arising during implantation of the prosthetic valve such as: inability to properly seat the valve in the annulus; need for more than one aortic bioprosthesis (valve in valve); or if a surgical aortic valve replacement is required to correct a severe aortic regurgitation or procedure complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Day of implant</time_frame>
    <description>3. Device success defined as:
Absence of intra-procedure mortality AND,
Correct positioning of a single prosthetic heart valve into the proper anatomical location AND,
Intended performance of the prosthetic heart valve (EOAi &gt;0.85 cm2/m2 and mean aortic valve gradient &lt;20mmHg without moderate or severe AR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC Composite Safety at 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement from baseline as per NYHA Functional Classification</measure>
    <time_frame>7 days, 30 days, 12 months post-implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in hemodynamic function: effective orifice area, mean transprosthetic gradient</measure>
    <time_frame>7 days, 30 days, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total aortic regurgitation</measure>
    <time_frame>7 days, 30 days, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>ACURATE neo AS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement</intervention_name>
    <description>Transcatheter aortic valve replacement via transfemoral access</description>
    <arm_group_label>ACURATE neo AS</arm_group_label>
    <other_name>ACURATE neo™ AS Aortic Bioprosthesis</other_name>
    <other_name>ACURATE neo™ AS TF Transfemoral Delivery System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient 75 years of age and older

          2. Severe aortic stenosis defined as:

               -  Mean aortic gradient &gt; 40 mmHg or

               -  Peak jet velocity &gt; 4.0 m/s or

               -  Aortic valve area of &lt; 1.0 cm2

          3. High risk candidate for conventional AVR defined as:

               -  Logistic EuroSCORE 1 ≥ 20% or

               -  STS Score ≥ 8% or

               -  Heart team (cardiologist and cardiac surgeon) consensus that patient is not a
                  surgical candidate for conventional AVR due to significant co-morbid conditions
                  unrelated to aortic stenosis

          4. NYHA Functional Class &gt; II

          5. Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by CT

          6. Patient willing to participate in the study and provides signed informed consent

        Exclusion Criteria:

          1. Congenital aortic stenosis or unicuspid or bicuspid aortic valve

          2. Non-stenotic Aortic Insufficiency

          3. Severe eccentricity of calcification

          4. Severe mitral regurgitation (&gt;2+)

          5. Presence of mitral bioprosthesis

          6. Presence of previously implanted aortic bioprosthesis

          7. Presence of prosthetic ring

          8. Anatomy NOT appropriate for transfemoral implant due to the size, disease and degree
             of calcification or tortuosity of the aorta or ilio-femoral arteries

          9. Thoracic (TAA) or abdominal (AAA) aortic aneurysm

         10. Presence of endovascular stent graft for treatment of TAA or AAA

         11. Trans-oesophageal echocardiogram (TEE) is contraindicated

         12. Evidence of intra-cardiac mass, thrombus or vegetation

         13. Severe ventricular dysfunction with ejection fraction &lt; 20%

         14. Any percutaneous intervention, except for balloon valvuloplasty (BAV) within 1 month
             prior to implant procedure

         15. Acute Myocardial Infarction within 1 month prior to implant procedure

         16. Previous TIA or stroke within 3 months prior to implant procedure

         17. Active ulcer or gastrointestinal (GI) bleeding within 3 months prior to implant
             procedure

         18. Any scheduled surgical or percutaneous procedure to be performed prior to 30 day visit

         19. Severe coagulation conditions

         20. Refusal of blood transfusions

         21. Systolic pressure &lt;80mmHg, cardiogenic shock, need for inotropic support or IABP

         22. Hypertrophic cardiomyopathy with or without obstruction

         23. Active bacterial endocarditis or other active infections

         24. Hepatic failure (&gt; Child B)

         25. Chronic renal dysfunction with serum creatinine &gt; 2.5 mg/dL or renal dialysis

         26. Refusal of surgery

         27. Severe COPD requiring home oxygen

         28. Neurological disease severely affecting ambulation or daily functioning, or dementia

         29. Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions

         30. Inability to tolerate anticoagulation therapy

         31. Contraindication to contrast media or allergy to nickel

         32. Currently participating in an investigational drug or another device study

         33. Non-valvular aortic stenosis

         34. Non-calcific acquired aortic stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helge Möllmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Innere Medizin - St.-Johannes-Hospital - Dortmund, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik Forschungsgesellschaft mbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle - Universitätsklinik und Poliklinik für Herzchirurgie</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg - Klinik und Poliklinik für Herz- und Gefäßchirurgie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>TAVI</keyword>
  <keyword>Transcatheter Aortic Valve Implant</keyword>
  <keyword>Transfemoral access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

